Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07736638
PHASE1

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-859 after single ascending doses in healthy adult volunteers.

Official title: A First-in-Human, Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-859 After Single Ascending Doses in Healthy Adult Subjects

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2026-07-28

Completion Date

2027-02

Last Updated

2026-07-30

Healthy Volunteers

Yes

Interventions

DRUG

ABBV-859

Oral Tablet

DRUG

Placebo for ABBV-859

Oral Tablet

DRUG

ABBV-859

Intravenous (IV) Infusion

DRUG

Placebo for ABBV-859

Intravenous (IV) Infusion